Add to a list

Inactive Instrument

Acura Pharmaceuticals, Inc. Stock Nasdaq

US00509L8028

Biotechnology & Medical Research

OTC Markets Traded

Valuation: Acura Pharmaceuticals, Inc.

Market Cap	3.28M 2.87M 2.64M 2.45M 4.64M 313M 4.72M 31.67M 12.42M 154M 12.31M 12.04M 532M	P/E 2020	-5.25x	P/E 2021	-25x
Enterprise Value	3.41M 2.99M 2.75M 2.55M 4.84M 326M 4.92M 32.98M 12.93M 160M 12.81M 12.54M 554M	EV / Sales 2020	2.91x	EV / Sales 2021	20.9x
Free-Float	98.31%	Yield 2020 *	-	Yield 2021	-

* Estimated data More valuation ratios

Latest news : Acura Pharmaceuticals, Inc.

06-24	Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	CI
05-29	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
03-10	Acura Pharmaceuticals, Inc. Receives Loans of $100,000 from Abuse Deterrent Pharma, LLC	CI
03-10	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
12-12	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
04/09/25	Acura Pharmaceuticals, Inc. Announces Loans from Abuse Deterrent Pharma, LLC	CI
03/09/25	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
18/07/25	Acura Pharmaceuticals, Inc. announced that it has received $8.394279 million in funding from Abuse Deterrent Pharma, LLC	CI
20/06/25	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
30/05/25	Acura Pharmaceuticals, Inc. Announces License, Development and Commercialization Agreement with AD Pharma	CI
30/05/25	Acura Pharmaceuticals, Inc. Amends Amend the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note with AD Pharma	CI
21/05/25	Acura Pharmaceuticals, Inc. and Abuse Deterrent Pharma, LLC Announces Second Meeting with US Food and Drug Administration	CI
23/04/25	Acura Pharmaceuticals, Inc. Receives Loan from Abuse Deterrent Pharma, LLC	CI

More news

Press Releases: Acura Pharmaceuticals, Inc.

16/12/24	Acura Pharmaceuticals : Financial Obligation Form 8 K	PU
26/07/24	Acura Pharmaceuticals : New Financial Obligation Form 8 K	PU
26/03/24	Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	PU
21/12/23	Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	PU
06/12/23	Acura Pharmaceuticals : New Financial Obligation - Form 8-K	PU

More press releases

Managers and Directors: Acura Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Jones CEO	Chief Executive Officer	67	01/04/2011
Bob Seiser DFI	Director of Finance/CFO	62	01/08/2024
Albert Brzeczko CTO	Chief Tech/Sci/R&D Officer	69	01/02/2009

Director	Title	Age	Since
Bruce Wesson BRD	Director/Board Member	83	01/03/1998
William Skelly CHM	Chairman	75	01/10/1996
Immanuel Thangaraj BRD	Director/Board Member	55	01/12/2002

More insiders

Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Employees

Sector

Biotechnology & Medical Research

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACURA PHARMACEUTICALS, INC.	-.--%	+4.44%	-	-	6.66K
ARGENX SE	+0.30%	-3.80%	+64.65%	+127.30%	56.98B
WUXI APPTEC CO., LTD.	+4.91%	-0.19%	+73.70%	+92.14%	53.58B
INSMED INCORPORATED	+1.48%	+5.97%	+22.59%	+495.47%	25.63B
BIONTECH SE	-0.59%	-4.68%	-16.82%	-12.99%	23.51B
WUXI BIOLOGICS (CAYMAN) INC.	+3.08%	+1.76%	+48.72%	+0.58%	19.43B
GENMAB A/S	-0.12%	+3.08%	+38.11%	-24.62%	18.12B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+203.03%	+348.11%	16.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.00%	+1.30%	+50.54%	-	14.13B
EXELIXIS, INC.	+1.76%	+2.24%	+29.57%	+195.70%	14.35B
Average	+1.04%	+0.86%	+57.12%	+152.71%	26.91B
Weighted average by Cap.	+1.51%	-0.31%	+57.53%	+143.33%

	2020	2021
Net sales	3.57M 3.12M 2.88M 2.66M 5.06M 341M 5.14M 34.49M 13.52M 167M 13.4M 13.11M 580M	1.56M 1.37M 1.26M 1.17M 2.21M 149M 2.25M 15.1M 5.92M 73.26M 5.87M 5.74M 254M
Net income	-1.21M -1.06M -975K -902K -1.71M -115M -1.74M -11.67M -4.57M -56.62M -4.53M -4.44M -196M	-879K -769K -709K -656K -1.25M -83.9M -1.27M -8.49M -3.33M -41.2M -3.3M -3.23M -143M
Net Debt	5.86M 5.12M 4.72M 4.37M 8.3M 559M 8.43M 56.57M 22.18M 274M 21.98M 21.51M 951M	135K 118K 109K 101K 191K 12.89M 194K 1.3M 511K 6.33M 507K 496K 21.92M

Acura Pharmaceuticals, Inc. Stock Nasdaq

Stocks

US00509L8028

Biotechnology & Medical Research

Valuation: Acura Pharmaceuticals, Inc.

Latest news : Acura Pharmaceuticals, Inc.

Press Releases: Acura Pharmaceuticals, Inc.

Managers and Directors: Acura Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile